Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests

The emergence of blood-based tests capable of detecting multiple cancers at once adds further complexity, raising concerns about false positives, diagnostic burden, and downstream effects on healthcare systems. Clear evidence standards are therefore needed before these new modalities are integrated into established screening programs.

University of Warwick (Coventry, UK) researchers, working with the UK National Screening Committee (UK NSC), have published position statements that set out how evidence should be generated and judged before introducing new screening approaches to patients. The guidance focuses on standards for surrogate outcomes in cancer screening trials and on requirements for multi-cancer detection (MCD) tests. It emphasizes that early signals of potential benefit must be interpreted alongside the full spectrum of harms and downstream system effects.

MCD tests are designed to identify several cancers from a single blood sample. The statements note that evaluating these assays is substantially more complex than assessing single-cancer tests because targeted cancers differ in natural history, existing pathways, and benefit-harm profiles. No country has yet introduced an MCD test within an organized program, underscoring the need for robust, use-case-specific evidence.

For surrogate outcomes, the UK NSC states that randomized controlled trials (RCTs) demonstrating mortality reduction remain the definitive benchmark. Surrogates such as reductions in late-stage disease can inform assessments of benefits and harms but cannot replace mortality at present because reliable, screening-specific validation methods are lacking. The guidance calls for further work to validate surrogate endpoints and supports adaptive, reversible implementation models, such as phased rollouts with predefined criteria for continuation or withdrawal, while longer-term mortality data continue to mature.

The statements also outline evaluation principles tailored to MCD tests. Evidence requirements should be specified by intended use (population-wide, high-risk targeting, or alongside existing breast, bowel, and cervical screening), with careful attention to false positives, diagnostic burden, equity, acceptability, and cost-effectiveness. The guidance highlights the NHS Galleri Trial in England, which has recruited 140,000 participants, and recommends reporting results by individual cancer type where feasible to clarify which cancers drive overall benefit. The positions were published in the BMJ on May 25, 2026.

"We want people to have access to effective cancer screening as quickly as possible, but only where the evidence shows it does more good than harm. This means making sure that any new cancer screening saves lives and doesn't give people incorrect test results or treatment that they do not need," said Professor Sian Taylor-Phillips, Professor of Population Health at the University of Warwick, lead for Warwick Screening, and member of the UK NSC.

"These position statements highlight the importance of considering the right evidence to inform policy decisions and using reversible rollout strategies to speed up evidence generation. Cancer screening, and multi-cancer detection in particular, is a fast-moving field, and we're committed to being open and adapting as the science develops," said Prof. Taylor-Phillips.

Related Links
University of Warwick
UK NSC